Your browser doesn't support javascript.
loading
A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.
Satwani, P; Ahn, K W; Carreras, J; Abdel-Azim, H; Cairo, M S; Cashen, A; Chen, A I; Cohen, J B; Costa, L J; Dandoy, C; Fenske, T S; Freytes, C O; Ganguly, S; Gale, R P; Ghosh, N; Hertzberg, M S; Hayashi, R J; Kamble, R T; Kanate, A S; Keating, A; Kharfan-Dabaja, M A; Lazarus, H M; Marks, D I; Nishihori, T; Olsson, R F; Prestidge, T D; Rolon, J M; Savani, B N; Vose, J M; Wood, W A; Inwards, D J; Bachanova, V; Smith, S M; Maloney, D G; Sureda, A; Hamadani, M.
Affiliation
  • Satwani P; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, NY, USA.
  • Ahn KW; CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA.
  • Carreras J; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Abdel-Azim H; CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, USA.
  • Cairo MS; Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
  • Cashen A; Pediatric Hematology/Oncology and Stem Cell Transplantation, New York Medical College, New York, NY, USA.
  • Chen AI; Division of Oncology, Washington University School of Medicine, St Louis, MO, USA.
  • Cohen JB; Oregon Health and Science University, Portland, OR, USA.
  • Costa LJ; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
  • Dandoy C; Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Fenske TS; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Freytes CO; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Ganguly S; South Texas Veterans Health Care System and University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
  • Gale RP; Blood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS, USA.
  • Ghosh N; Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
  • Hertzberg MS; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, USA.
  • Hayashi RJ; Department of Haematology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
  • Kamble RT; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, MO, USA.
  • Kanate AS; Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA.
  • Keating A; Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
  • Kharfan-Dabaja MA; Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Lazarus HM; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Marks DI; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
  • Nishihori T; Pediatric Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, UK.
  • Olsson RF; Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Prestidge TD; Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Rolon JM; Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden.
  • Savani BN; Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.
  • Vose JM; Bone Marrow Transplante Unit, FUNDALEU, Buenos Aires, Argentina.
  • Wood WA; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Inwards DJ; Department of Internal Medicine, The Nebraska Medical Center, Omaha, NE, USA.
  • Bachanova V; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
  • Smith SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
  • Maloney DG; Bone and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
  • Sureda A; Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA.
  • Hamadani M; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bone Marrow Transplant ; 50(11): 1416-23, 2015 Nov.
Article in En | MEDLINE | ID: mdl-26237164
ABSTRACT
Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pretransplant factors predictive of outcomes of AutoHCT in children, adolescents and young adults (CAYA, age <30 years). In a retrospective study, we analyzed 606 CAYA patients (median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995 and 2010. The probabilities of PFS at 1, 5 and 10 years were 66% (95% confidence interval (CI) 62-70), 52% (95% CI 48-57) and 47% (95% CI 42-51), respectively. Multivariate analysis for PFS demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score ⩾90, no extranodal involvement and chemosensitive disease had significantly improved PFS. Patients with time from diagnosis to first relapse of <1 year had a significantly inferior PFS. A prognostic model for PFS was developed that stratified patients into low-, intermediate- and high-risk groups, predicting for 5-year PFS probabilities of 72% (95% CI 64-80), 53% (95% CI 47-59) and 23% (95% CI 9-36), respectively. This large study identifies a group of CAYA patients with relapsed/refractory HL who are at high risk of progression after AutoHCT. Such patients should be targeted for novel therapeutic and/or maintenance approaches post-AutoHCT.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Hematopoietic Stem Cell Transplantation / Models, Theoretical Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Language: En Journal: Bone Marrow Transplant Year: 2015 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hodgkin Disease / Hematopoietic Stem Cell Transplantation / Models, Theoretical Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Language: En Journal: Bone Marrow Transplant Year: 2015 Document type: Article